U.S. spending on biosimilars by type 2014

This statistic displays the annual spending on biosimilars in the United States in 2014, by type. During this year, 8.6 billion U.S. dollars that were spent on insulins were to expire between 2015 and 2019. In 2009, the Biologics Price Competition and Innovation Act established a biosimilar pathway which has led to several applications and approvals.

本统计数据展示了2014年美国生物类似物年度支出情况，按类型划分。当年，用于胰岛素的86亿美元支出预计将在2015年至2019年间到期。2009年，《生物制品价格竞争与创新法案》确立了生物类似物途径，该法案的实施催生了多项申请及批准。